The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 164:525-a, March 2007
doi: 10.1176/appi.ajp.164.3.525-a
© 2007 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by FINK, M.
* Articles by TAYLOR, M. A.
* Search for Related Content
PubMed
* Articles by FINK, M.
* Articles by TAYLOR, M. A.
Related Collections
* DSM

Letter to the Editor

Drs. Fink and Taylor Reply

MAX FINK, M.D., and MICHAEL ALAN TAYLOR, M.D.
St. James, N.Y.

To The Editor: Catatonia is a syndrome defined by two or more persistent clinical signs cited in catatonia rating scales (1, 2). It is commonly identified in patients with depressive illness, manic-depression, and psychotic disorder. It is frequently seen in patients with seizure disorder, frontal circuitry brain disease, and in toxic metabolic states (1). Dr. Balhara objects to the suggestion that the rapid relief of catatonia by the intravenous administration of lorazepam or amobarbital verifies the diagnosis in subjects who meet the clinical criteria. He recognizes that catatonic features are not specific to a single condition and cites elective mutism as an example of a condition that does not meet the criteria for catatonia and yet responds to amobarbital assisted interviews.

In 1930, barbiturates were replaced by benzodiazepines for reasons of safety. In recent trials among patients who meet rating scale criteria for catatonia, more than 80% of patients had a rapid reduction in symptoms with an intravenous lorazepam challenge (1, 2). Such a response to lorazepam typically results in a lorazepam treatment trial, followed by electroconvulsive therapy if substantial relief is not maintained. Adhering to this algorithm achieves remission of catatonia in almost all patients.

Dr. Balhara notes that conversion disorders like mutism "are associated with features that do resemble catatonia and do respond to amobarbital assisted interview" as a negation of the lorazepam challenge test as verification of the diagnosis. In his example, however, the patient with elective mutism and "associated features [of catatonia]" would meet the diagnostic criteria for catatonia, and the relief afforded by amobarbital would verify the diagnosis and encourage the prescription of effective treatments of the syndrome.

References

  1. Fink M, Taylor MA: Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge, UK, Cambridge University Press, 2003
  2. Bush G, Fink M, Petrides G, Dowling F, Francis A: Catatonia, II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137–143[Medline]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by FINK, M.
* Articles by TAYLOR, M. A.
* Search for Related Content
PubMed
* Articles by FINK, M.
* Articles by TAYLOR, M. A.
Related Collections
* DSM


Get information about faster international access.

Privacy Policy

Copyright © 2007 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org